Manuel Domine

Manuel Domine

Fundacion Jimenez Diaz - / Spain
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4990930
Fundació Jimenez Diaz
person_outline Manuel Domine's MOST POPULAR ARTICLES
1-) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... N engl J med 375, 1823-1833, 2016 82472016
2-) Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 81162015
3-) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 56022012
4-) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancerL Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ...New England journal of medicine 378 (22), 2078-2092, 201861072018
5-) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLCMA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...New England Journal of Medicine 378 (24), 2288-2301, 201835712018